Skip to main content
. 2022 Sep 23;149(8):4533–4545. doi: 10.1007/s00432-022-04194-9

Table 1.

Patients’ characteristics

Characteristics No. of patients %
Age (years)
 < 60 3 9.4
 ≥ 60 and < 70 14 43.8
 ≥ 70 and < 80 9 28.1
 ≥ 80 6 18.8
Hormone therapy before CIRT (months)
 0 3 9.4
 < 6 26 81.3
 ≥ 6 3 9.4
T stage
 T1 1 3.1
 T2 25 78.1
 T3 5 15.6
 T4 1 3.1
Initial PSA (ng/ml)
 < 10 17 53.1
 ≥ 10 and ≤ 20 9 28.1
 > 20 6 18.8
Gleason score
 6 8 25.0
 7 12 37.5
 ≥ 8 12 37.5
Risk (NCCN)
 Low 1 3.1
 Intermediate 15 46.9
 High 10 31.3
 Very high 6 18.8
Simultaneous integrated boost (SIB)
 Yes 15 46.9
 No 17 53.1